NVAX Novavax Inc

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

$192.53  +0.29 (0.15%)
As of 06/24/2021 15:59:47 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/05/1995
Outstanding shares:  74,094,435
Average volume:  4,394,339
Market cap:   $14,401,735,331
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    670002401
ISIN:        US6700024010
Sedol:      BJDQXG4
Valuation   (See tab for details)
PE ratio:   -23.16
PB ratio:   13.70
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy